This suggests that the senescent phenotypes of SPC are reversible and salvageable only in the early stages. Previous evidence suggests that there is an interaction and regulatory relationship between Erk1/2 and p38 MAPK, and Erk1/2 has been confirmed to be significantly activated in Crouzon syndrome. The gene discussed is MAPK3; the disease is Crouzon syndrome.